Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 11057 - 11064 of 12007 results
IRS, Treasury Department Issue Proposed Rules Governing Minimum Value, Affordability, and Wellness Programs
May 16, 2013| Advisory| Viewpoint
New York City Passes Earned Sick Time Act; Expects to Override Mayor Bloomberg's Threatened Veto Yet Again
May 15, 2013| Blog| Viewpoint
July 1 COPPA Compliance Deadline is Approaching
May 15, 2013| Blog| Viewpoint
Five Years in the Making - IRS Releases Findings from Colleges and Universities Compliance Project
May 13, 2013| Blog| Viewpoint
Five Takeaways from the OIG’s Special Advisory Bulletin on Exclusion
May 10, 2013| Advisory| Viewpoint
EU Data Protection Regulation: and the horizon recedes again . . .
May 10, 2013| Blog| Viewpoint
How to Minimize FCPA Risk in Health Care Acquisitions
May 10, 2013| Blog| Viewpoint
Final Medical Marijuana Regulations Approved in Massachusetts
May 10, 2013| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|